The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Depression affects approximately 2.5% of children and 8% of adolescents. Escitalopram is the
S-enantiomer of citalopram. Both escitalopram and citalopram are selective serotonin reuptake
inhibitors (SSRIs) and are used to treat depression in adults. This study is designed to
provide a systematic evaluation of the safety and efficacy of escitalopram in the treatment
of depressed pediatric patients, 12 to 17 years of age. Patients completing the study will be
eligible to enter an open-label extension study.